Asad Haider
Stock Analyst at Goldman Sachs
(2.90)
# 1,596
Out of 5,150 analysts
15
Total ratings
71.43%
Success rate
23.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Upgrades: Buy | $115 → $142 | $102.49 | +38.55% | 2 | Jan 16, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $213 → $240 | $239.26 | +0.31% | 3 | Dec 19, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Neutral | $30 → $37 | $30.16 | +22.68% | 2 | Dec 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $57 | $60.92 | -6.43% | 2 | Dec 2, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $22.27 | -23.66% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $46.29 | -9.27% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $58.49 | -35.03% | 1 | Sep 12, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $984.16 | -9.77% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $230.73 | -15.92% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $26.42 | -5.37% | 1 | Apr 8, 2025 |
BioNTech SE
Jan 16, 2026
Upgrades: Buy
Price Target: $115 → $142
Current: $102.49
Upside: +38.55%
Johnson & Johnson
Dec 19, 2025
Maintains: Buy
Price Target: $213 → $240
Current: $239.26
Upside: +0.31%
NewAmsterdam Pharma Company
Dec 2, 2025
Maintains: Neutral
Price Target: $30 → $37
Current: $30.16
Upside: +22.68%
Bristol-Myers Squibb Company
Dec 2, 2025
Maintains: Neutral
Price Target: $51 → $57
Current: $60.92
Upside: -6.43%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $22.27
Upside: -23.66%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $46.29
Upside: -9.27%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $58.49
Upside: -35.03%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $984.16
Upside: -9.77%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $230.73
Upside: -15.92%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $26.42
Upside: -5.37%